Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
Erratum issued 2 registry-linked trialsAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 41 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer
OvS Breast: ENBI Project, Ovarian Suppression in Breast Cancer: Exercise, Nutrition and Behavioural Intervention Project
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Recovery of ovarian function after chemotherapy in premenopausal women with breast cancer: a systematic review and meta-analysis.Breast cancer research and treatment · 2026Pooled it
- Recent advances in non-pharmacological interventions for symptom burden management in breast cancer patients treated with ovarian function suppression.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025.Current oncology (Toronto, Ont.) · 2026Guideline
- Trial
- Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial.Breast cancer research and treatment · 2024Trial
- Optimizing Extended Adjuvant Endocrine Therapy in Early HR+/HER2- Breast Cancer: The Emerging Role of Genomic Assays and ctDNA MRD.Advances in therapy · 2026Review
- Article
- Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026Article
- Chemobrain as a Neuroimmune Syndrome: Mechanisms, Modifiers, and Emerging Multi-Target Therapeutic Strategies.Molecules (Basel, Switzerland) · 2026Review
- LRRC8A: A multifaceted regulator in cancer, neurological disorders, metabolic diseases and immune modulation.Genes & diseases · 2026Review
- Ovarian function suppression decision-making and uptake in premenopausal women with breast cancer: a mixed methods analysis.Breast cancer research and treatment · 2026Article
- The 19th St. Gallen international breast cancer conference 'primary therapy of patients with early breast cancer. Evidence, controversies, consensus': key moments and breakthroughs.Ecancermedicalscience · 2026Article
- Tamoxifen-induced neutropenia and leukopenia in a breast cancer patient: a case report and literature review.Frontiers in oncology · 2026Article
- Review
- Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index.JAMA network open · 2025Article
- Adherence to adjuvant endocrine therapy including GnRH-analogues and survival: a population-based cohort study.EClinicalMedicine · 2025Article
- Article
- Clinicopathological characteristics and prognostic outcomes of young adult women (aged 18-30 years) with breast cancer in Ahmedabad, India: a single-centre, retrospective observational study.The Lancet regional health. Southeast Asia · 2025Article
- Overexpression of KIF2C amplifies tamoxifen resistance and lung metastasis of breast cancer through PLK1/C-Myc pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
28 authors.
Prudence A FrancisSir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Australia.ORCID 0000-0002-7207-9286
Gini F FlemingThe University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL.ORCID 0000-0003-2845-4023
István LángClinexpert-Research, Budapest, Hungary.
Eva M CiruelosMedical Oncology Department, University Hospital and SOLTI Breast Cancer Research Cooperative Group, Madrid, Spain.ORCID 0000-0002-2796-1042
Hervé R BonnefoiInstitut Bergonié Comprehensive Cancer Centre, Université de Bordeaux, INSERM U1312, and European Organisation for Research and Treatment of Cancer (EORTC), Bordeaux, France.ORCID 0000-0003-4293-9748
Meritxell BelletVall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, and SOLTI Breast Cancer Research Cooperative Group, Barcelona, Spain.ORCID 0000-0001-8859-8307
Antonio BernardoMedical Oncology Unit, ICS Maugeri-IRCCS, Pavia, Italy.
Miguel A ClimentInstituto Valenciano de Oncologia, Valencia and SOLTI Breast Cancer Research Cooperative Group, Barcelona, Spain.
Silvana MartinoThe Angeles Clinic and Research Institute and SWOG, Santa Monica, CA.
Begoña BermejoDepartment of Medical Oncology, Hospital Clínico Universitario de Valencia, Incliva, Barcelona, Spain.ORCID 0000-0001-7773-5994
Harold J BursteinSusan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School and Alliance for Clinical Trials in Oncology, Boston, MA.ORCID 0000-0003-1963-8162
Nancy E DavidsonFred Hutchinson Cancer Center, University of Washington and ECOG-ACRIN, Seattle, WA.
Charles E GeyerUniversity of Pittsburgh Medical Center Hillman Cancer Center and NRG Oncology, Pittsburgh, PA.
Barbara A WalleyUniversity of Calgary and Canadian Cancer Trials Group, Calgary, Alberta, Canada.ORCID 0000-0002-9618-905X
James N IngleMayo Clinic and Alliance for Clinical Trials in Oncology, Rochester, MN.ORCID 0000-0003-1257-7731
Robert E ColemanWeston Park Hospital, Sheffield, United Kingdom.ORCID 0000-0002-4275-1043
Bettina MüllerChilean Cooperative Group for Oncological Research (GOCCHI), Santiago, Chile.ORCID 0000-0002-8589-5725
Fanny Le DuDepartment of Medical Oncology, Centre Eugène Marquis, Rennes, France.ORCID 0000-0002-4372-5832
Sibylle LoiblGerman Breast Group, Neu-Isenburg, Germany.ORCID 0000-0001-6488-4958
Eric P WinerSusan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School and Alliance for Clinical Trials in Oncology, Boston, MA.ORCID 0000-0002-8819-1723
Barbara RueppInternational Breast Cancer Study Group Coordinating Center, Bern, Switzerland.
Sherene LoiInternational Breast Cancer Study Group and Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0001-6137-9171
Marco ColleoniDivision of Medical Senology, IEO, European Institute of Oncology, IRCCS and International Breast Cancer Study Group, Milan, Italy.ORCID 0000-0002-5743-3013
Alan S CoatesInternational Breast Cancer Study Group and University of Sydney, Sydney, Australia.ORCID 0000-0002-0141-7356
Richard D GelberInternational Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, Frontier Science Foundation, Boston, MA.ORCID 0000-0001-8270-8712
Aron GoldhirschIEO, European Institute of Oncology, IRCCS and International Breast Cancer Study Group, Milan, Italy.
Meredith M ReganInternational Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0002-2428-6109
SOFT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation)
Funding
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8MMember Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6MSWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1MStatistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam, GREG YOTHERS · 2014 to 2026
$146.4MNRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5MStatistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · 2014 to 2026
$111.2MNCIC Clinical Trials Group - Canadian Collaborating Clinical Trials NetworkU10CA180863 · NCI · QUEEN'S UNIVERSITY AT KINGSTON · PI Janet Ellen Dancey · 2014 to 2026
$40.4MUT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1UG1CA233329 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KELLY K HUNT, CHELSEA Camille PINNIX · 2019 to 2026
$11.1MIBCSG STATISTICAL CENTER--A BREAST CANCER STUDY RESOURCEU24CA075362 · NCI · DANA-FARBER CANCER INSTITUTE · PI REGAN, MEREDITH M · 1997 to 2015
$7.5MUM LAPs -UG1 GrantUG1CA233160 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANNE F SCHOTT · 2019 to 2026
$5.4MHutchinson Center as Lead Academic Participating Site (UG1)UG1CA233328 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Evan Yu · 2019 to 2026
$4.3MCancer Research UK C1491/A15955Cancer Research UK CRUKE/03/022Cancer Research UK CRUKE/03/023NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180863NCI NIH HHS U10 CA180868NCI NIH HHS U10 CA180888NCI NIH HHS U24 CA075362NCI NIH HHS UG1 CA189867NCI NIH HHS UG1 CA233160NCI NIH HHS UG1 CA233328NCI NIH HHS UG1 CA233329
Abstract
PubMed holds no abstract for this paper.
Indexed as
Breast NeoplasmsAdjuvants, ImmunologicAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalFemaleHumansPremenopauseTamoxifenAdjuvants, ImmunologicAntineoplastic Agents, HormonalTamoxifen
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT00066690ClinicalTrials.gov
NCT06727487ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.